Banu K. Arun, MD
Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.
during the meeting, Arun discussed the challenge of treating these patients, the value of genotyping, and what she hopes to see in future trial results.
OncLive: What were some key points of your lecture?
As you know, women with germline BRCA
mutations mostly have high-grade cancers, especially BRCA1
-related breast cancers. They have more triple-negative disease and more aggressive cancers. Recently, new approaches have been evaluated in these patients, including PARP inhibitors. I reviewed 2 very recently reported phase III studies looking at singleagent PARP inhibitors versus physician’s choice of therapy.
We don’t have any predictive biomarkers of response and we are just now beginning to do targeted therapy with immunotherapy and immunomodulation targeting the PI3K/AKT/mTOR pathway. We targeting the androgen receptor in TNBC. I reviewed the principles of these approaches but none of them are standard of care yet, unfortunately. We are still treating TNBC with standard therapies.
Has genotyping become more important since LOTUS was reported?
The LOTUS trial looked at an AKT inhibitor plus chemotherapy versus chemotherapy alone. The combination was significantly better than single-agent chemotherapy.
... to read the full story